FAST NEWS: Everest Medicines Plunges After Terminating Breast Cancer Drug Deal
The latest: Everest Medicines Ltd. (1952.HK) announced Tuesday that it is terminating its agreement to develop Gilead Science’s (GILD.US) Sacituzumab Govitecan breast cancer drug for the China market. Looking up:…
RELATED ARTICLES
-
Everest reaches new heights on growing drug sales
1952.HK
-
FAST NEWS: Everest Medicines gets new drug license from Kezar Life
1952.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
Discover hidden China stock gems in our weekly newsletter